Talk:Ancillary testing in prostate cancer: Difference between revisions

Revision as of 15:17, 1 November 2022 view source Michael (talk \| contribs) 49,358 edits Created page with "MSI testing - in BRCA1/2: {{cite journal \|vauthors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R..."		Latest revision as of 15:20, 1 November 2022 view source Michael (talk \| contribs) 49,358 edits No edit summary
Line 1:		Line 1:
	MSI testing - in BRCA1/2: {{cite journal \|~~vauthors~~=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O \|title=Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA \|journal=J Immunother Cancer \|volume=8 \|issue=2 \|pages= \|date=August 2020 \|pmid= \|pmc=7422632 \|doi=10.1136/jitc-2020-001065 \|url=}}		MSI testing - in BRCA1/2: {{cite journal \|authors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O \|title=Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA \|journal=J Immunother Cancer \|volume=8 \|issue=2 \|pages= \|date=August 2020 \|pmid= \|pmc=7422632 \|doi=10.1136/jitc-2020-001065 \|url=}}

Navigation menu